Morbid obesity and bariatric surgery
Stem
A 42-year-old man, 158 kg, 175 cm (BMI 52), is scheduled for laparoscopic sleeve gastrectomy. He snores loudly, his wife has witnessed apneas, and he has never had a sleep study. Neck circumference is 49 cm, Mallampati III. Serum bicarbonate is 30 mmol/L. He takes semaglutide, on a stable dose for six months, and denies nausea or bloating.
Question
How will you plan his anesthetic, from induction through his postoperative disposition?
Ideal answer
HeadlineHigh-risk airway with untreated OSA: ramped, preoxygenated to end-tidal O2 0.9, video laryngoscope, monitored bed afterward.
- Semaglutide continued, liquid diet for 24 hours beforehand, because the dose is stable and he is asymptomatic;1 gastric ultrasound before induction. The bicarbonate sends me looking for obesity hypoventilation and pulmonary hypertension.
- Ramped, external auditory meatus level with sternal notch; preoxygenated head-up by tight-fitting mask or high-flow nasal oxygen to end-tidal oxygen above 0.9, with apneic oxygenation during laryngoscopy.
- Video laryngoscope, second-generation supraglottic airway ready; propofol and rocuronium on lean weight, succinylcholine on total weight.
- Ideal-body-weight tidal volumes, PEEP, recruitment, because lungs scale with height and collapse under weight; multimodal opioid-sparing analgesia, full reversal, awake semi-upright extubation.
- Monitored bed with continuous oximetry, because his apnea is untreated: not an unmonitored floor with a PCA.
Breaking down the answer
- Ramped and head-up — aligns the airway axes and raises functional residual capacity, extending safe apnea time from about 1–2 minutes to several minutes in a morbidly obese patient.
- Rapid sequence or not — obesity alone does not mandate it; gastric volume and pH are similar to lean patients. I use it for reflux, diabetic gastroparesis, GLP-1 use with symptoms or in dose escalation, or a full stomach on ultrasound.
- GLP-1 agonists — most patients continue them; risk is highest in dose escalation, on higher doses, or with active nausea, vomiting, pain or constipation. I defer elective surgery for escalation or symptoms and treat a full antrum as a full stomach.1
- Dosing scalar — succinylcholine on total weight because pseudocholinesterase activity and volume of distribution rise;2 sugammadex on actual weight, which in the label's BMI ≥40 trial reversed faster than ideal-weight dosing;3 opioids on lean weight and titrated.
- Ventilation — 6–8 mL/kg ideal body weight, PEEP 8–10 cmH2O or higher with pneumoperitoneum, and recruitment, because atelectasis forms within minutes of induction.
- Disposition — the examiner grades judgment here: continuous oximetry or a monitored bed for untreated or severe OSA, opioid-requiring patients and those with hypoventilation.
- VTE prophylaxis — obesity and laparoscopy raise risk; mechanical and pharmacologic prophylaxis and early ambulation.
Follow-up question
After induction, mask ventilation is difficult and the first video laryngoscopy attempt fails. The SpO2 is 88% and falling. What do you do?
Follow-up answer
HeadlineA failing airway in a patient with minimal oxygen reserve; I call for help and announce the situation.
I place a second-generation supraglottic airway to oxygenate rather than make repeated attempts. If oxygenation improves, I decide with the team whether to intubate through it with a flexible scope or to wake him. If I cannot oxygenate, I declare CICO and perform a front-of-neck airway, scalpel-bougie-tube, with a vertical skin incision because landmarks are hard to palpate. I reassess saturation and end-tidal CO2 after each step. Airway ultrasound to mark the cricothyroid membrane before induction would have reduced this risk.
Pitfalls that cost points
- Treating obesity alone as an indication for rapid sequence.
- Extubating deep or supine in a patient with OSA.
Rapid-fire
Q: Why do obese patients desaturate so quickly? A: FRC falls below closing capacity and oxygen consumption is higher; the oxygen reservoir is smaller and used faster.
Q: Why does obesity hypoventilation syndrome matter? A: Daytime hypercapnia, blunted CO2 drive, pulmonary hypertension and high risk of postoperative respiratory failure; a bicarbonate of 28 mmol/L or more also raises the probability of significant OSA.4
Q: Why is the blood pressure cuff a problem? A: A cuff that is too small overestimates pressure; I use the correct size, a forearm cuff, or an arterial line.
Q: What is the leak test after sleeve gastrectomy? A: The surgeon asks for methylene blue or air through an orogastric tube, so I coordinate tube placement and withdraw it before stapling.
Numbers to know
| Item | Value |
|---|---|
| Class III obesity | BMI ≥ 40 kg/m² |
| STOP-BANG high risk | 5–8; 3–4 upgraded by BMI > 35, neck > 40 cm, male sex or HCO3 ≥ 284 |
| Preoxygenation target | End-tidal O2 ≥ 0.9 |
| Tidal volume | 6–8 mL/kg ideal body weight |
| PEEP | 8–10 cmH2O or more |
| Ideal body weight (men) | 50 kg + 2.3 kg per inch over 5 ft |
| Sugammadex scalar | Actual body weight: 2, 4 or 16 mg/kg by depth of block3 |
Links
- Obstructive sleep apnea, Anticipated difficult airway and the ASA algorithm, Rapid sequence induction and full stomach, laparoscopy, Pulmonary embolism
- Atlas: Abdominal free fluid and gastric ultrasound; Airway ultrasound structures (2027)
- ASA Practice Guidelines for Perioperative Management of Patients with OSA; ASA Practice Guidelines for Management of the Difficult Airway (2022); Multisociety clinical guidance on GLP-1 receptor agonists (2024)
Sources
- 1.New Multi-society Clinical Practice Guidance Released (GLP-1 receptor agonists) · ASA / AGA / ASMBS / ISPCOP / SAGES, 2024 · asahq.org
- 2.Obesity: succinylcholine dosing · OpenAnesthesia · openanesthesia.org
- 3.BRIDION (sugammadex) injection prescribing information · Merck / FDA label · merck.comSection 2.1 dosing on actual body weight; section 8.10 obese patients.
- 4.SLEEP STRATEGIES: The flexibility of STOP-Bang Questionnaire to screen for OSA: A practical approach · CHEST Physician (Chung and Nagappa) · blogs.the-hospitalist.org0–2 low, 5–8 high; 3–4 upgraded by BMI >35, neck >40 cm, male sex or HCO3 ≥28 mmol/L.
Facts on this page were checked against these sources on Oct 14, 2026. Guidelines change; confirm doses against current institutional protocols.